ESMO Strikes Directly at the First Prospective Study: An Exploration of the Mechanism of Oshitinib Resistance

The European Society for Internal Oncology (ESMO) Annual Meeting is the most prestigious and influential oncology conference

In the oral presentation, Professor Zofia Piotrowska presented the results of the ELIOS study, which for the first time prospectively explored the mechanism

Professor Zofia Piotrowska

1

background

Third-generation EGFR TKI ositinib is the preferred first-line treatment for

method

Patients with EGFR-TKI initial treatment of advanced EGFR-sensitive mutation NSCLC are treated

outcome

A total of 154 patients were included in the study (full set of analyses; FAS), median age was 62 years, 77% were Asians, and 55%, 38%, and 7%

conclusion

Only 46 paired samples with valid NGS results were collected in patients with disease progression, suggesting the challenge of
obtaining a more comprehensive, non-invasive approach to obtaining disease progression tissue biopsy samples.

MET amplification (17%) and overexpression (50%) and EGFR C797S (15%) are the main mechanisms of acquired resistance to ositinib, consistent
with previous study data.

NKX2.
1 amplification is one of the newly discovered potential mechanisms of
drug resistance.

In the ELIOS study, the efficacy and safety of first-line ositinib was consistent
with the FLAURA study.

Histological data cannot be proactively collected from tissue samples and will be collected retrospectively and analyzed
.


LBA53-ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with First-line (1L) Osimertinib Editor: Small Garden Typesetting: Small Garden Execution: Small Garden